Free Trial
NASDAQ:SCNI

Scinai Immunotherapeutics Q4 2025 Earnings Results & Report

Scinai Immunotherapeutics logo
$0.40 0.00 (0.00%)
Closing price 11/13/2026 03:58 PM Eastern
Extended Trading
$0.42 +0.02 (+5.25%)
As of 11/13/2026 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Scinai Immunotherapeutics reported Q4 2025 earnings on April 1, 2026. The company reported EPS of $38.00, while revenue was $269 thousand.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Scinai Immunotherapeutics EPS Results

Actual EPS
$38.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Scinai Immunotherapeutics Revenue Results

Actual Revenue
$269 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Scinai Immunotherapeutics' Q3 2026 earnings is estimated for Wednesday, December 2, 2026, based on past reporting schedules

Scinai Immunotherapeutics Q4 2025 Earnings FAQ

Scinai Immunotherapeutics (NASDAQ:SCNI) reported earnings of $38.00 per share for Q4 2025. The report was announced on Wednesday, April 1, 2026.

Scinai Immunotherapeutics reported revenue of $269 thousand for Q4 2025.

Scinai Immunotherapeutics' next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Scinai Immunotherapeutics on the company's earnings history page.

Scinai Immunotherapeutics Earnings Headlines

The warning signs most investors see too late
Dr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.tc pixel
See More Scinai Immunotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scinai Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scinai Immunotherapeutics and other key companies, straight to your email.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics (NASDAQ:SCNI) Ltd. (NASDAQ:SCNI) is an Israel-based clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for autoimmune and inflammatory diseases. The company’s research is centered on treatments intended to modulate disease-related immune responses while potentially limiting systemic exposure and associated side effects.

Scinai’s technology platform is based on NanoAb antibody fragments, which are designed to bind specific biological targets and may be suitable for local administration. The company has focused its development efforts on therapies for inflammatory skin conditions, including plaque psoriasis, with programs directed at interleukin-17A, a cytokine associated with inflammatory and autoimmune disorders.

In addition to advancing its own product candidates, Scinai has indicated that its NanoAb platform may support partnerships and licensing opportunities for the development of other targeted immunotherapies. The company is headquartered in Israel and conducts its research and development activities through its proprietary platform and external collaborations.

View Scinai Immunotherapeutics Profile